Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Doglioni

Showing results (371-380 of 831) with videos related to

Pageof 84
Sort By:
Blood|November 15, 1996
p21/WAF1 cyclin-kinase inhibitor expression in non-Hodgkin's lymphomas: a potential marker of p53 tumor-suppressor gene functionM Chilosi, C Doglioni, A Magalini, et al.
European Urology|October 8, 2008
Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapyAlberto Briganti, Jeffrey R Karnes, Luigi Filippo Da Pozzo, et al.
The Journal of Maternal-Fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians|October 13, 2015
Delivery room management of extremely low birth weight infants in Italy: comparison between academic and non-academic birth centresVeronica Mardegan, Irene Satariano, Nicoletta Doglioni, et al.
The Lancet. Gastroenterology & Hepatology|September 18, 2018
Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trialMichele Reni, Silvia Zanon, Umberto Peretti, et al.
Cancer Cell|September 15, 2012
A "twist box" code of p53 inactivation: twist box: p53 interaction promotes p53 degradationSara Piccinin, Elena Tonin, Sara Sessa, et al.
Pathology Oncology Research : POR|June 15, 2026
Proof-of-principle 4-marker spatial profiling reveals distinct, location-independent immune clusters in biliary tract cancersFederico Rossari, Michele Sala, Margherita Rimini, et al.
Blood|April 30, 2011
Tumor-associated macrophages as major source of APRIL in gastric MALT lymphomaFabio Munari, Silvia Lonardi, Marco A Cassatella, et al.
Cancer Chemotherapy and Pharmacology|June 1, 2011
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen)Michele Reni, Stefano Cereda, Alessia Rognone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinomaM Reni, S Zanon, G Balzano, et al.
Scientific Reports|September 22, 2017
New insights into earthquake precursors from InSARMarco Moro, Michele Saroli, Salvatore Stramondo, et al.
Pageof 84

Showing results (371-380 of 831) with videos related to

Sort By:
Pageof 84
Blood|November 15, 1996
p21/WAF1 cyclin-kinase inhibitor expression in non-Hodgkin's lymphomas: a potential marker of p53 tumor-suppressor gene functionM Chilosi, C Doglioni, A Magalini, et al.
European Urology|October 8, 2008
Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapyAlberto Briganti, Jeffrey R Karnes, Luigi Filippo Da Pozzo, et al.
The Journal of Maternal-Fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians|October 13, 2015
Delivery room management of extremely low birth weight infants in Italy: comparison between academic and non-academic birth centresVeronica Mardegan, Irene Satariano, Nicoletta Doglioni, et al.
The Lancet. Gastroenterology & Hepatology|September 18, 2018
Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trialMichele Reni, Silvia Zanon, Umberto Peretti, et al.
Cancer Cell|September 15, 2012
A "twist box" code of p53 inactivation: twist box: p53 interaction promotes p53 degradationSara Piccinin, Elena Tonin, Sara Sessa, et al.
Pathology Oncology Research : POR|June 15, 2026
Proof-of-principle 4-marker spatial profiling reveals distinct, location-independent immune clusters in biliary tract cancersFederico Rossari, Michele Sala, Margherita Rimini, et al.
Blood|April 30, 2011
Tumor-associated macrophages as major source of APRIL in gastric MALT lymphomaFabio Munari, Silvia Lonardi, Marco A Cassatella, et al.
Cancer Chemotherapy and Pharmacology|June 1, 2011
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen)Michele Reni, Stefano Cereda, Alessia Rognone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinomaM Reni, S Zanon, G Balzano, et al.
Scientific Reports|September 22, 2017
New insights into earthquake precursors from InSARMarco Moro, Michele Saroli, Salvatore Stramondo, et al.
Pageof 84